Cyclerion therapeutics Contact Number

All Time Past 24 Hours Past Week Past month Post Your Comments?

Listing Results Cyclerion therapeutics Contact Number

Contact • Cyclerion

4 hours ago Cyclerion.com Show details

857-327-8778

Cyclerion Therapeutics 245 First Street Riverview II, 18th Floor Cambridge, MA 02142. Phone: 857-327-8778 Email: [email protected]cyclerion.com Fax: 617-890-6595

Category: Contact SupportShow more

Cyclerion

6 hours ago Cyclerion.com Show details

Focus, Forward. Our focus is on unlocking the full therapeutic potential of the NO-cGMP pathway to address a broad range of serious CNS diseases. We have the expertise, team and determination to bring innovative medicines forward for patients.

Category: Contact NumberShow more

Cyclerion Therapeutics, Inc. Company Profile Cambridge

Just Now Dnb.com Show details

(857) 327-8778

Cyclerion Therapeutics, Inc. is located in Cambridge, MA, United States and is part of the Pharmaceutical and Medicine Manufacturing Industry. Cyclerion Therapeutics, Inc. has 143 total employees across all of its locations and generates $2.30 million in sales (USD). There are 2 companies in the Cyclerion Therapeutics, Inc. corporate family.

Employees: 143
Phone: (857) 327-8778
Location: 301 Binney St, Cambridge, 02142-1071, MA

Category: Contact NumberShow more

SEC Filing Cyclerion Therapeutics, Inc.

9 hours ago Ir.cyclerion.com Show details

(857) 327-8778

Cyclerion Therapeutics, Inc. Street Address 1 Street Address 2; 245 First Street, 18th Floor: City State/Province/Country ZIP/PostalCode Phone Number of Issuer; CAMBRIDGE: MASSACHUSETTS: 02142 (857) 327-8778

Category: Contact NumberShow more

Cyclerion Therapeutics Crunchbase Company Profile & Funding

6 hours ago Crunchbase.com Show details

Cyclerion Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products.

Founder: Peter M. Hecht
Location: Cambridge, Massachusetts
Founded: Jan 01, 2019

Category: Contact NumberShow more

Cyclerion Therapeutics, Inc. (CYCN) Company Profile

6 hours ago Stockanalysis.com Show details

Company profile for Cyclerion Therapeutics, Inc. (CYCN) with a description, list of executives, contact details and other key facts. Company profile for Cyclerion Therapeutics, Inc. (CYCN) with a description, list of executives, contact details and other key facts. CUSIP Number: 23255M105: ISIN Number: US23255M1053: Employer ID: 83-1895370

Category: Contact NumberShow more

Cyclerion LinkedIn

2 hours ago Linkedin.com Show details

Cyclerion 2,804 followers on LinkedIn. Unlocking the full therapeutic potential of the NO-cGMP pathway to address a broad range of serious CNS diseases Cyclerion Therapeutics is a clinical

Category: Contact NumberShow more

Contact Celleron Therapeutics

4 hours ago Cellerontherapeutics.com Show details

Here are the contact details for Celleron Therapeutics. Want to get in touch? Here are the contact details for Celleron Therapeutics. Phone Please enter a valid phone number. Your Message Please type your message. SEND [email protected]cellerontherapeutics.com. Terms and Conditions

Category: Cell Phone, Contact SupportShow more

Cyclerion Therapeutics, Inc. (CYCN) Company Profile

5 hours ago Finance.yahoo.com Show details

See the company profile for Cyclerion Therapeutics, Inc. (CYCN) including business summary, industry/sector information, number of employees, business summary, corporate governance, key …

Category: Contact NumberShow more

Cyclerion Therapeutics, Inc. (Form: DEF 14A, Received: 04

Just Now Content.edgar-online.com Show details

A copy of the Company’s Annual Report to the Securities and Exchange Commission on Form 10-K for the fiscal year ended December 31, 2020 is available without charge upon written request to Cyclerion Therapeutics, 245 First Street, 18 th Floor, Cambridge, Massachusetts 02142, …

Category: Contact NumberShow more

A Study of the Effects of CY6463 in Participants With

7 hours ago Clinicaltrials.gov Show details

You have reached the maximum number of saved studies (100). To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies. Cyclerion Therapeutics: More Information.

Category: Contact NumberShow more

Phase 2a Study of IW6463 in Adults Diagnosed With MELAS

7 hours ago Clinicaltrials.gov Show details

Cyclerion Therapeutics: ClinicalTrials.gov Identifier: NCT04475549 Other Study ID Numbers: C6463-201 CY6463 ( Other Identifier: Cyclerion Therapeutics ) First Posted: July 17, 2020 Key Record Dates: Last Update Posted: September 16, 2021 Last Verified: September 2021

Category: Contact NumberShow more

Cyclerion Therapeutics Hosted Webinar to Discuss Pipeline

3 hours ago Ir.cyclerion.com Show details

Cyclerion Therapeutics Hosted Webinar to Discuss Pipeline Progress. April 27, 2021 at 9:00 AM EDT. PDF Version. Provided updates on development strategy and execution for CY6463, a first-in-class, CNS-penetrant sGC stimulator, including IND clearance from FDA in ADv and ongoing MELAS program. Introduced new CY6463 clinical program in CIAS with

Category: Contact NumberShow more

Community Collaboration to Push Clinical Trials Forward

Just Now Mitoaction.org Show details

Cyclerion Therapeutics has an ongoing clinical study in patients with Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like episodes (MELAS) that’s evaluating the investigational drug 6463. The study is a 29 day study and looks at safety and tolerability primarily …

Category: Contact NumberShow more

Cyclerion Therapeutics Funding, Financials, Valuation

5 hours ago Crunchbase.com Show details

Cyclerion Therapeutics has raised a total of $217M in funding over 3 rounds. Their latest funding was raised on Jun 4, 2021 from a Post-IPO Equity round. Cyclerion Therapeutics is registered under the ticker NASDAQ:CYCN . Cyclerion Therapeutics is funded by 8 investors. MFN Partners and Peter M. Hecht are the most recent investors.

Category: Contact NumberShow more

Cyclerion Therapeutics Number of Employees 20182021

9 hours ago Macrotrends.net Show details

Cyclerion Therapeutics number of employees from 2018 to 2021. Number of employees can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures, expressed on a per share basis. Cyclerion Therapeutics Inc. is a clinical-stage biopharmaceutical company harnessing the power of sGC pharmacology to

Category: Contact NumberShow more

Cyclerion fails sickle cell test, prompting pivot to CNS

1 hours ago Fiercebiotech.com Show details

Cyclerion Therapeutics has stopped development of olinciguat in sickle cell disease after getting a look at data from a phase 2 trial. The setback prompted Cyclerion to switch its …

Category: Cell PhoneShow more

Cyclerion Therapeutics' : Preclinical Trial Shows CY6463

9 hours ago Marketscreener.com Show details

Cyclerion Therapeutics' : Preclinical Trial Shows CY6463 May Have Potential Against Multiple Central Nervous System Diseases 09/22/2021 10:39am EDT Send by mail :

Category: Contact NumberShow more

Cyclerion Therapeutics, Inc. Common Stock (CYCN) Insider

7 hours ago Nasdaq.com Show details

Cyclerion Therapeutics, Inc. Common Stock (CYCN) Nasdaq Listed. Nasdaq 100. Data is currently not available. $3.44. +0.06 (+1.78%) DATA AS OF Sep 27, 2021. Add to Watchlist. Add to Portfolio.

Category: Contact NumberShow more

Cyclerion VentureRadar

8 hours ago Ventureradar.com Show details

Listed Company. "Cyclerion Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop and commercialize breakthrough treatments for serious and orphan diseases. Cyclerion is advancing its portfolio of differentiated sGC stimulator programs with distinct

Category: Contact NumberShow more

CYCN SEC Filings Cyclerion Therapeutics Inc 10K and

Just Now Fintel.io Show details

019-05-13

2019-05-13. 10-Q. CYCN / Cyclerion Therapeutics, Inc. 10-Q Quarterly Report 10-Q. Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 or o TRANSITION

Category: Contact NumberShow more

Is Cyclerion Therapeutics, Inc. (CYCN) A Good Stock To Buy?

2 hours ago Finance.yahoo.com Show details

Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) was in 6 hedge funds' portfolios at the end of the third quarter of 2020. The all time high for this statistics is 17. The all time high for this

Category: Contact NumberShow more

How to buy Cyclerion Therapeutics stock 28 Sept price $3.09

8 hours ago Finder.com Show details

Posted Jul 15, 2021. Fact checked. Cyclerion Therapeutics is a biotechnology business based in the US. Cyclerion Therapeutics stocks (CYCN.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $3.77 – an increase of 9.46% over the previous week. Cyclerion Therapeutics employs 34 staff and has a

Category: Contact NumberShow more

Cyclerion Therapeutics : Cantor Fitzgerald Starts

9 hours ago Marketscreener.com Show details

September 30, 2021. Cyclerion Therapeutics : Cantor Fitzgerald Starts Cyclerion Therapeutics at Overweight with $7 Price Target

Category: Contact NumberShow more

Top Small Molecule startups VentureRadar

3 hours ago Ventureradar.com Show details

Cyclerion Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop and commercialize breakthrough treatments for serious and orphan diseases.

Category: Contact NumberShow more

Nic Betts Senior Director, Head of IT and Facilities

6 hours ago Linkedin.com Show details

Ironwood separation (Cyclerion IT design & implementation) Aug 2018 - Apr 2019 Developed the technology strategy, and implementation of that strategy, for the Ironwood spinout, Cyclerion.

Title: Senior Director, Head of IT and …
Location: Cambridge, Massachusetts
1. 500+ connections

Category: Contact NumberShow more

Working at Cyclerion Therapeutics Glassdoor

1 hours ago Glassdoor.com Show details

Glassdoor gives you an inside look at what it's like to work at Cyclerion Therapeutics, including salaries, reviews, office photos, and more. This is the Cyclerion Therapeutics company profile. All content is posted anonymously by employees working at Cyclerion Therapeutics.

Category: Contact NumberShow more

CYCN Cyclerion Therapeutics Inc. • BioPharmCatalyst

5 hours ago Biopharmcatalyst.com Show details

Presenter: Chris Winrow, Ph.D., Head of Translational Medicine, Cyclerion Therapeutics, Inc. Date: Thursday, August 26, 2021 Time: 2:30 p.m. ET followed by a live Q&A at 3:00 p.m. ET. About Cyclerion Therapeutics Cyclerion Therapeutics is a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function.

Category: Contact NumberShow more

Should You Accumulate Cyclerion Therapeutics Inc (CYCN

6 hours ago Investorsobserver.com Show details

Cyclerion Therapeutics Inc has a Long-Term Technical rank of 25. This means that trading over the last 200 trading days has placed the company in the lower half of stocks with 75% of the market scoring higher. In the Biotechnology industry which is number 130 by this metric, CYCN ranks better than 49% of stocks. Important Dates for Investors in

Category: Contact NumberShow more

Cyclerion Therapeutics, Inc. (Form: 10K, Received: 03/12

5 hours ago Content.edgar-online.com Show details

For the transition period from ___ to ___. Commission file number: 001-38787 CYCLERION THERAPEUTICS, INC. (Exact Name of registrant as specified in its charter)

Category: Contact NumberShow more

This $4.13 Biotech Stock Just Broke Out Trades Of The Day

7 hours ago Tradesoftheday.com Show details

Note that the stop loss is on a closing basis. Our target potential upside is 95% to 221%. For a risk of $1.76, our first target reward is $4.14, and the second target reward is $9.64. This is a nearly 1:2 and 1:6 risk-reward trade. In other words, this trade …

Category: Tech SupportShow more

CYCN SEC Filings Cyclerion Therapeutics Inc Annual

8 hours ago Fintel.io Show details

021-02-08

(Name of Issuer) Common Stock, no par value per share (Title of Class of Securities) 23255M 105 (CUSIP Number) Cyclerion Therapeutics, Inc. 201 Binney Street Cambridge, MA 02142 (Name, Address and Telephone Number of Person Au. 2021-02-08: SC 13G/A: SC 13G/A

Category: Contact NumberShow more

Peter M. Hecht Net Worth, Biography & Insider Trading History

7 hours ago Insidertrades.com Show details

Peter M. Hecht has not been actively trading shares of Cyclerion Therapeutics within the last three months. Most recently, on Thursday, June 3rd, Peter M. Hecht bought 823,170 shares of Cyclerion Therapeutics stock. The stock was acquired at an average cost of $3.28 per share, with a total value of $2,699,997.60.

Category: Contact NumberShow more

Terrance Mcguire Net Worth, Biography & Insider Trading

Just Now Insidertrades.com Show details

Terrance Mcguire has not been actively trading shares of Cyclerion Therapeutics during the last ninety days. Most recently, on Thursday, June 3rd, Terrance Mcguire bought 96,153 shares of Cyclerion Therapeutics stock. The stock was acquired at an average cost of …

Category: Contact NumberShow more

Premarket Mover: Cyclerion Therapeutics Inc (CYCN) Down 5.06%

9 hours ago Investorsobserver.com Show details

Cyclerion Therapeutics Inc (Cyclerion Therapeutics Inc has fallen Friday morning, with the stock decreasing -5.06% in pre-market trading to 3.94.CYCN's short-term technical score of 14 indicates that the stock has traded less bullishly over the last month than 86% of stocks on the market.

Category: Contact NumberShow more

Member Spotlight: Q&A with Cyclerion Therapeutics MassBio

9 hours ago Massbio.org Show details

Cyclerion is a biotech company focused on discovering, developing, and delivering medicines that treat serious and orphan diseases. Our efforts are centered on a powerful target, called soluble guanylate cyclase (sGC). sGC is located throughout the body and is a critical regulator of a number of biological functions that are essential for human health, such as blood flow, metabolism

Category: Contact NumberShow more

Cyclerion Therapeutics (NasdaqGS:CYCN) Share price, News

Just Now Simplywall.st Show details

Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. More Details.

Category: Contact NumberShow more

5 Best Biotech Penny Stocks to Buy Now Insider Monkey

1 hours ago Insidermonkey.com Show details

Number of Hedge Fund Holders: 9 . Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) is a Boston-based biopharma firm founded in 2018. It is placed fifth …

Category: Tech SupportShow more

Beacon Biosignals and Cyclerion Therapeutics Announce

1 hours ago Prnewswire.com Show details

BOSTON, July 8, 2021 /PRNewswire/ -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) and Beacon Biosignals today announced an extended and expanded strategic partnership between the two companies

Category: Contact NumberShow more

Cyclerion Therapeutics, Inc. S1 Apr. 18, 2019 5:04 PM

9 hours ago Seekingalpha.com Show details

About: Cyclerion Therapeutics, Inc. (CYCN) View as PDF Cyclerion Therapeutics, Inc. (Form: S-1, Received: 04/18/2019 17:06:10) Use these links to rapidly review the document

Category: Contact NumberShow more

Cyclerion Therapeutics PE Ratio 20182021 CYCN MacroTrends

8 hours ago Macrotrends.net Show details

Current and historical p/e ratio for Cyclerion Therapeutics (CYCN) from 2018 to 2021. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure.

Category: Contact NumberShow more

American Society of Nephrology Kidney Week Abstract

2 hours ago Asn-online.org Show details

202-640-4660

Contact ASN. 1401 H St, NW, Ste 900, Washington, DC 20005. [email protected] 202-640-4660

Category: Contact NumberShow more

5 Best Biotech Penny Stocks to Buy Now Insider Monkey

4 hours ago Insidermonkey.com Show details

1. Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) Number of Hedge Fund Holders: 8. (NASDAQ: SPPI) is a Nevada-based biopharma company founded in 1987.
2. Sesen Bio, Inc. (NASDAQ: SESN) Number of Hedge Fund Holders: 11. (NASDAQ: SESN) is a Massachusetts-based biotechnology company founded in 2008.
3. Hoth Therapeutics, Inc. (NASDAQ: HOTH) Number of Hedge Fund Holders: 3. (NASDAQ: HOTH) is a New York-based biotechnology company founded in 2017.
4. Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) Number of Hedge Fund Holders: 14. (NASDAQ: PIRS) is a Boston-based biotechnology company founded in 2000.
5. Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) Number of Hedge Fund Holders: 9. (NASDAQ: CYCN) is a Boston-based biopharma firm founded in 2018.

Category: Tech SupportShow more

CYCN Cyclerion Therapeutics Stock Options Prices

1 hours ago Barchart.com Show details

Volume: The total number of option contracts bought and sold for the day, for that particular strike price. Open Interest: Open Interest is the total number of open option contracts that have been traded but not yet liquidated via offsetting trades for that date. Vol/OI - for the Strike Price: today's volume / today's open interest. A higher

Category: Contact NumberShow more

Cyclerion Therapeutics to Present Clinical Trial Design

1 hours ago Apnews.com Show details

Cyclerion Poster Presentation Details: Title: Clinical trial design for a Phase 2a study evaluating the safety, tolerability, pharmacokinetics, and CNS activity of CY6463 in participants with Alzheimer’s disease with vascular pathology. Poster Number: P-54463. Presenter: Chad Glasser, Ph.D., Director of Clinical Research, Cyclerion Therapeutics

Category: Contact NumberShow more

What Do Analysts Say About Cyclerion Therapeutics Inc

5 hours ago Baxterreport.com Show details

Cyclerion Therapeutics Inc. (CYCN) saw downtrend of -1.25% in the recent trading with $3.15 being its most recent. The current price level -64.84% lower than the highest price of $8.96 marked by the stock while trading over the past 52-weeks, whereas it is 51.44% higher than the lowest price of $2.08 the company dropped to over past 52-weeks.

Category: Contact NumberShow more

CYCN Biotech Message Board Posts

7 hours ago Investorvillage.com Show details

July 22, 2021 04:31 PM ET (BZ Newswire) -- News . Cyclerion Therapeutics, Inc. (NASDAQ:CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, today announced that it will present clinical trial design for a Phase 2a study of its lead development candidate, CY6463, in participants with Alzheimer’s disease with vascular …

Category: Tech SupportShow more

SRO List Food and Drug Administration

2 hours ago Accessdata.fda.gov Show details

3. SRO List. -. You can search the list by entering the DUNS NUMBER, BUSINESS NAME, or TICKER SYMBOL in the search criteria. The SRO list is a comprehensive and important resource to check regularly, however, it is not definitive. There are some situations where a financial interest may constitute a prohibited financial interest in an SRO, even

Category: Contact NumberShow more

All Time Past 24 Hours Past Week Past month

Please leave your comments here:

Brand New Updated

Frequently Asked Questions

How to contact cyclerion therapeutics in cambridge ma?

Contact Us Cyclerion Therapeutics 245 First Street Riverview II, 18th Floor Cambridge, MA 02142 Phone: 857-327-8778 Email: [email protected] Fax: 617-890-6595 Investor Relations or Media Inquiries: [email protected] Partnering Inquiries: [email protected] Sponsorship Inquiries: [email protected] © 2021 Cyclerion Therapeutics, Inc.

What kind of governance does cyclerion therapeutics have?

Cyclerion Therapeutics, Inc.’s ISS Governance QualityScore as of July 1, 2021 is 3. The pillar scores are Audit: 3; Board: 4; Shareholder Rights: 2; Compensation: 7. Corporate governance scores courtesy of Institutional Shareholder Services (ISS).

What do we need to know about cyclerion pipeline?

Our pipeline is focused on programs for serious CNS diseases. Learn more about neurophysiology and the importance of NO-sGC-cGMP signaling in the CNS.

Brand New Updated

Popular Brands

Costco
Cisco
Cae
Ccu
Crh